Design Therapeutics Inc

NASDAQ DSGN

Data sourced from

and

Download Data

Design Therapeutics Inc Net Operating Profit After Tax (NOPAT) 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 30, 2023: -32.03%

Design Therapeutics Inc Net Operating Profit After Tax (NOPAT) 1 year YoY Change (%) is -32.03% for the Trailing 12 Months (TTM) ending September 30, 2023. Net Operating Profit After Taxes (NOPAT) is a financial metric that represents a company's operating profit after deducting taxes. It is calculated by multiplying the earnings before interest and taxes (EBIT) by (1 - tax rate). NOPAT provides insights into the company's profitability from its core operations while accounting for the impact of taxes. It is useful for assessing the company's operating performance and comparing profitability across different tax environments. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Design Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2023 was -17,082,046.82, a -41.37% change year over year.
Design Therapeutics Inc Net Operating Profit After Tax (NOPAT) for the Trailing 12 Months (TTM) ending March 31, 2022 was -12,082,965.00.

NASDAQ: DSGN

Design Therapeutics Inc

CEO	Dr. João Siffert M.D.
IPO Date	March 26, 2021
Location	United States
Headquarters	6005 Hidden Valley Road, Carlsbad, CA, United States, 92011
Employees	57
Sector	Healthcare
Industry	Biotechnology

Description

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Key trends